Antineutrophil cytoplasmic antibodies in patients with Graves' disease: Association of antimyeloperoxidase autoantibodies with propylthiouracil therapy

Modern Rheumatology

Volumn 13, Issue 4, 2003, Pages 305-312

  Honda, Hirokazu ^a   Shibata, Takanori ^a   Hara, Hideo ^b   Ban, Yoshio ^b   Sugisaki, Tetsuzo ^a  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SHOWA UNIVERSITY   (Japan)

Author keywords

Antimyeloperoxidase autoantibodies (MPO ANCA); Graves' disease; Propylthiouracil (PTU)

Indexed keywords

AUTOANTIBODY; CREATININE; DNA ANTIBODY; DOUBLE STRANDED DNA; IMMUNOGLOBULIN G ANTIBODY; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PROPYLTHIOURACIL; RHEUMATOID FACTOR; SINGLE STRANDED DNA; THIAMAZOLE; THYROID PEROXIDASE ANTIBODY;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BLOOD SAMPLING; CELL NUCLEUS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULONEPHRITIS; GRAVES DISEASE; HASHIMOTO DISEASE; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; MOLECULAR WEIGHT; NEUTROPHIL; PRIORITY JOURNAL; VASCULITIS; WESTERN BLOTTING;

EID: 1142299540     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-003-0252-7     Document Type: Article

References (34)

1. Gross WL, Schmitt WH, Csernok E. ANCA and associated diseases: immunodiagnostic and pathogenetic aspects. Clin Exp Immunol 1993;91:1-12.
2. Kallenberg CGM, Brouwer E, Weening JJ, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential. Kidney Int 1994;46:1-15.
3. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997;337:1512-23.
4. Stankus SJ, Johnson NT. Propylthiouracil-induced hypersensitivity vasculitis presenting as respiratory failure. Chest 1992;102:1595-6.
5. Dolman KM, Gans ROB, Vervaat TJ, Zevenbergen G, Maingay D, Nikkels RE, et al. Vasculitis and antineutrophil cytoplasmic autoantibodies associated with propylthiouracil therapy. Lancet 1993;342:651-2.
6. Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A. Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 1994;124:986-8.
7. Tanemoto M, Miyakawa H, Hanai J, Yago M, Kitaoka M, Uchida S. Myeloperoxidase-antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis complicating the course of Graves' disease: report of three adult cases. Am J Kidney Dis 1995;26:774-80.
8. D'Cruz D, Chesser AMS, Lightowler C, Comer M, Hurst MJ, Baker LRI, et al. Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol 1995;34:1090-1.
9. Romas E, Henderson DRF, Kirkham BW. Propylthiouracil therapy: an unusual cause of antineutrophil cytoplasmic antibody associated alveolar hemorrhage. J Rheumatol 1995;22:803.
10. Gunton JE, Stiel J, Caterson RJ, McElduff A. Anti-thyroid drugs and antineutrophil cytoplasmic antibody positive vasculitis. A case report and review of the literature. J Clin Endcrinol Metab 1999; 84:13-6.
11. Kobayashi K, Shibata T, Sugisaki T. Aggravation of rat nephrotoxic serum nephritis by anti-myeloperoxidase antibodies. Kidney Int 1995:47:454-63.
12. Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988;318:1651-7.
13. Shibata T, Berney T, Spertini F, Izui S. Rheumatoid factors in mice bearing the lpr or gld mutation. Selective production of rheumatoid factor cryoglobulins in MRL/MPJ-lpr/lpr mice. Clin Exp Immunol 1992;87:190-5.
14. Johnson DA, Gautsch JW, Sportsman JR, Elder JH. Improved technique utilizing nonfat dry milk for analysis of proteins and nucleic acids transferred to nitrocellulose. Gene Anal Tech 1984; 1:3-8.
15. Olsen RL, Little C. Studies on the subunits of human myeloperoxidase. Biochem J 1984;222:701-9.
16. Andrews PC, Krinsky NI. The reductive cleavage of myeloperoxidase in half, producing enzymically active hemimyeloperoxidase. J Biol Chem 1981;256:4211-8.
17. Andersen MR. Atkin CL, Eyre HJ. Intact form of myeloperoxidase from normal human neutrophils. Arch Biochem Biophys 1982;214:273-83.
18. Sera N, Ashizawa K, Ando T, Abe Y, Ide A, Usa T, et al. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease. Thyroid 2000;10:595-9.
19. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000;85:4270-3.
20. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A. Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving anti-thyroid medication. Eur J Endocrinol 2000;142:587-90.
21. Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N. Prevalence of serum anti-myeloperoxidase antineutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. Endocr J 2002;49: 329-34.
22. Noh JY, Asari T, Hamada N, Makino F, Ishikawa N, Abe Y, et al. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves'-disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations. Clin Endocrinol 2001;54:651-4.
23. Cooper DS. Antithyroid drugs. N Engl J Med 1984;311:1353-62.
24. 14C] propylthiouracil in human polymorphonuclear leukocytes. Biochem Pharmacol 1979;28:2289-96.
25. Lee E, Hirouchi M, Hosokawa M, Sayo H, Kohno M, Kariya K. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol 1988;37:2151-3.
26. Lee E, Miki Y, Katsura H, Kariya K. Mechanism of inactivation of myeloperoxidase by propylthiouracil. Biochem Pharmacol 1990; 39:1467-71.
27. Wing SS, Fantus IG. Adverse immunologic effects of antithyroid drugs. Can Med Assoc J 1987;136:121-7.
28. Falk RJ, Becker M, Tervell R, Jennette JC. Anti-myeloperoxidase autoantibodies react with native but not denatured myeloperoxidase. Clin Exp Immunol 1992;89:274-8.
29. Audrain MAP, Baranger TAR, Moguilevski N, Martin SJ, Devys A, Lockwood CM, et al. Anti-native and recombinant myeloperoxidase monoclonals and human autoantibodies. Clin Exp Immunol 1997;107:127-34.
30. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87:4115-9.
31. Ewert BH, Jennette JC, Falk RJ. Anti-myeloperoxidase antibodies stimulate neutrophils to damage human endothelial cells. Kidney Int 1992;41:375-83.
32. Savage COS, Pottinger BE, Gaskin G, Pusey CD, Pearson JD. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992;141:335-42.
33. Jennette JC, Falk RJ. Pathogenesis of the vascular and glomerular damage in ANCA-positive vasculitis. Nephrol Dial Transplant 1998;13 Suppl 1:16-20.
34. Savage COS. ANCA-associated renal vasculitis. Kidney Int 2001; 60:1614-27.